Clinical trials: Schizoaffective Disorders
Diabetes, Obesity
Healthy Lifestyles for Mentally Ill People Who Have Experienced Weight Gain From Their Antipsychotic Medications
This program aims to help Veterans who take antipsychotic medications lose weight. The investigators use a program based on the American Diabetes Association's "Diabetes Prevention Program," and the investigators have modified it…
- Conditions
- Diabetes, Obesity, Weight Gain
- Trial name
- MAMAO (NCT00344500)
- Testing
- Behavioral Weight Loss Program
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- VA Office of Research and Development
Schizophrenia, Schizoaffective Disorder
Pregnenolone for Cognitive and Negative Symptoms in Schizophrenia
This study will investigate adjunctive pregnenolone for patients with schizophrenia and schizoaffective disorder.
- Trial name
- NCT00728728
- Testing
- Dietary Supplement: Pregnenolone
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- VA Office of Research and Development
Insomnia, Schizophrenia
Randomized, Controlled, Double Blind Trial of Eszopiclone for Insomnia Associated With Schizophrenia
The major goal of this project is to investigate established insomnia treatments in a schizophrenia population to see if the improved sleep leads to overall better quality of life.
- Conditions
- Insomnia, Schizophrenia, Schizoaffective Disorder, Sleep Disorders
- Trial name
- NCT00645944
- Testing
- Eszopiclone
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Yale University
Bipolar Disorder, Schizoaffective Disorder
Effects of Pentazocine Versus Lorazepam on Manic Symptoms
Pilot data indicates that pentazocine decreases manic symptoms in hospitalized individuals. To follow up these initial findings, we plan to conduct a larger, more rigorous, double-blind study.
- Conditions
- Bipolar Disorder, Schizoaffective Disorder, Manic Disorder, Mania
- Trial name
- NCT00431184
- Testing
- Pentazocine, Lorazepam
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Mclean Hospital
Schizophrenia
Pharmacologically-augmented Cognitive Therapies (PACTs) for Schizophrenia.
This application seeks renewed support for MH59803, "Dopaminergic substrates of startle gating across species," to extend a clear path of "bench-to-bedside" progress towards a critical paradigm shift in therapeutic models for…
- Trial name
- NCT02634684
- Testing
- Dextroamphetamine
- Where
- United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
Schizophrenia, Schizoaffective Disorder
Lurasidone Effects on Tissue Glutamate in Schizophrenia
24 individuals with schizophrenia or schizoaffective disorders, who are currently considered stable, will be recruited, screened for entry criteria into a blinded study with a 4-week randomization to either lurasidone…
- Trial name
- NCT02199743
- Testing
- Lurasidone, Haloperidol, Perphenazine
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Texas Southwestern Medical Center
Post Traumatic Stress Disorder, Schizophrenia
PTSD (PostTraumatic Stress Disorder) Services for Veterans With SMI (Severe Mental Illness)
As in the general population, there is no clear standard of care within Veterans Affairs Medical Centers for treating posttraumatic stress disorder (PTSD) among individuals with severe mental illness (SMI).
- Conditions
- Post Traumatic Stress Disorder, Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- PTSD/SMI (NCT01542229)
- Testing
- Prolonged Exposure for PTSD (PE) + Treatment as Usual (TAU), Treatment As Usual (TAU)
- Where
- United States
- Volunteers
- 134 people
- Sponsor
- VA Office of Research and Development
Schizophrenia Schizoaffective
A Multiple Dose Study to Assess the Safety, Tolerability and PK of Risperidone Extended Release Capsules
Lyndra is developing an oral, extended release (ER) formulation of risperidone (LYN-005) presented in a capsule dosage form with the intent of reducing the frequency of dosing orally-administered medications to once weekly or…
- Trial name
- NCT04567524
- Testing
- LYN-005
- Where
- 5 sites in United States
- Volunteers
- 34 people
- Sponsor
- Lyndra Inc.
Schizophrenia, Schizoaffective Disorder
Optimizing Response in Psychosis Study
The purpose of this project is to evaluate the efficacy of long-acting risperidone for patients with first episode schizophrenia spectrum who did not improve sufficiently with the first antipsychotic medication they tried during…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorder Not Otherwise Specified
- Trial name
- ORP (NCT00314327)
- Testing
- long-acting injectable risperidone
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Northwell Health
Major Depression, Bipolar Depression
The Use of Galantamine HBr (Reminyl) in Electroconvulsive Therapy: Impact on Mood and Cognitive Functioning
The purpose of the study is to see if galantamine HBr (Razadyne) is safe and can help treat problems with thinking and memory caused by electroconvulsive therapy (ECT).
- Conditions
- Major Depression, Bipolar Depression, Schizoaffective Disorder
- Trial name
- Galantamine (NCT00566735)
- Testing
- Razadyne
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Massachusetts General Hospital
Schizophrenia, Schizoaffective Disorder
Tocilizumab as Add-On Treatment For Residual Positive, Negative, and Cognitive Symptoms of Schizophrenia
Randomized, double-blind clinical trial of tocilizumab vs. placebo as add-on treatment for residual positive, negative, and cognitive symptoms in schizophrenia.
- Trial name
- NCT02034474
- Testing
- Tocilizumab
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- New York State Psychiatric Institute
Schizophrenia, Schizoaffective Disorder
Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Schizophrenia
This study in patients with schizophrenia is designed to provide preliminary evidence of the safety, tolerability, and pharmacokinetics as well as the effects on cognitive function of 2 doses of EVP-6124 compared with placebo…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Central Nervous System Diseases
- Trial name
- NCT01556763
- Testing
- EVP-6124 (0.3 mg/day), EVP-6124 (1.0 mg/day), Antipsychotic therapy
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- FORUM Pharmaceuticals Inc
Schizophrenia, Depression
Quetiapine Extended Release Depression Symptoms
Aim of the study is to assess if the new compound Seroquel XR™ is non-inferior to Risperidone, considered as the reference drug for the treatment of depressive symptoms of schizophrenia.
- Trial name
- ExAttitude (NCT00640562)
- Testing
- Quetiapine Extended Release, Risperidone
- Where
- 21 sites in Italy
- Volunteers
- 216 people
- Sponsor
- AstraZeneca
Schizophrenia, Schizophrenia Schizoaffective
Focused Ultrasound Modulation of the Globus Pallidus Interna in Schizophrenia
This is a single-site, phase 2, sham-controlled random-order cross-over pilot trial of PLIFUS targeting the right GPi in individuals with schizophrenia.
- Trial name
- NCT05643196
- Testing
- PLIFUS, MRI
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- NYU Langone Health
Schizophrenia, Schizoaffective Disorder
A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder
This study will investigate the efficacy and safety of RO6889450 as monotherapy in participants experiencing an acute exacerbation of symptoms of schizophrenia or schizoaffective disorder.
- Trial name
- NCT04512066
- Testing
- RO6889450, Risperidone
- Where
- 40 sites in United States, Japan and 2 more
- Volunteers
- 287 people
- Sponsor
- Hoffmann-La Roche
Schizophrenia, Hallucinations
Transcranial Magnetic Stimulation for "Voices"
This study will determine the efficacy of MRI-guided transcranial magnetic stimulation (TMS)in reducing "voices" and other symptoms experienced by people with schizophrenia and schizoaffective disorder.
- Trial name
- NCT00308997
- Testing
- 1-hertz Repetitive Transcranial Magnetic Stimulation, Active 1-Hertz Repetitive transcranial magnetic stimulation
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- Yale University
Agitation, Schizophrenia
Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia
This is a definitive study to support the safety and efficacy evaluation of BXCL501 for the acute treatment of agitation in schizophrenia.
- Conditions
- Agitation, Schizophrenia, Schizo Affective Disorder, Schizoaffective Disorder
- Trial name
- SERENITY I (NCT04268303)
- Testing
- Sublingual film containing dexmedetomidine (BXCL501)
- Where
- 15 sites in United States
- Volunteers
- 380 people
- Sponsor
- BioXcel Therapeutics Inc
Acute Schizophrenia, Schizoaffective Disorder
RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder
The objective of this study is to evaluate the efficacy and safety of RP5063 relative to placebo for the treatment of schizophrenia or schizoaffective disorder.
- Trial name
- REFRESH (NCT01490086)
- Testing
- RP5063, aripiprazole
- Where
- 15 sites in United States, India and 3 more
- Volunteers
- 234 people
- Sponsor
- Reviva Pharmaceuticals
Schizophrenia, Schizoaffective Disorder
Biomarker Study of Acamprosate in Schizophrenia
NMDA receptors are brain receptors that are stimulated by glutamate. Poorly functioning NMDA receptors are thought to be involved in the pathology of schizophrenia.
- Trial name
- NCT00688324
- Testing
- Acamprosate
- Where
- 4 sites in United States
- Volunteers
- 36 people
- Sponsor
- University of Maryland, Baltimore
Psychosis, Substance Use
Families With Substance Use and Psychosis: A Pilot Study
The purpose of this study is to develop and evaluate an intervention that adapts Community Reinforcement and Family Training (CRAFT) for families experiencing first episode psychosis and substance use delivered via telemedicine…
- Conditions
- Psychosis, Substance Use, Substance Use Disorders, Family
- Trial name
- NCT04284813
- Testing
- CRAFT-FT
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Mclean Hospital